Lupin Ltd has received tentative approval from the US Food and Drug Administration (FDA) for its New Drug Application (NDA) for Apixaban Oral Suspension 1.25 mg/mL through the 505(b)(2) regulatory pathway. The product is a liquid formulation of apixaban, the active ingredient in Bristol Myers Squibb’s Eliquis, and is designed to provide an alternative administration […]